

The logo for Seeking Alpha, with the text 'Seeking Alpha' in white and a gold Greek letter alpha symbol to the right, all on a dark red background.

GTx Inc Q4 2008 Earnings Call Transcript

Earnings Call Excerpt

GTx Inc (GTXI)

Q4 2008 Earnings Call

February 17, 2009; 09:00 am ET

Executives

Mitchell Steiner - Vice Chairman and Chief Executive Officer

Marc Hanover - President and Chief Operating Officer

Mark Mosteller - Chief Financial Officer

McDavid Stilwell - Director of Corporate Communications

Analysts

Eric Schmidt - Cowen & Company

Howard Liang - Leerink Swann

Joel Sendek - Lazard Capital Markets

Simos Simeonidis - Rodman & Renshaw

Aaron Reames - Wachovia Capital Markets

Presentation

Operator

Good day, ladies and gentlemen and welcome to the GTx fourth quarter and year-end 2008 conference call. My name is Ann and I'll be your coordinator for today's call (Operator Instructions).

I would now like to turn the presentation over to Mr. McDavid Stilwell, Director of Corporate Communications. Please Proceed.

McDavid Stilwell

On behalf of GTx, I'd like to welcome you to our fourth quarter and year-end 2008 conference call. We released our financial results earlier this morning through the newswires. If you do not have a copy of the release, you will find it on our website at www.gtxinc.com. We'll have a replay of this call available on our website until March 3, 2009.

With me today are Dr. Mitchell Steiner, Vice Chairman and Chief Executive Officer; Marc Hanover, President and Chief Operating Officer, and Mark Mosteller, Chief Financial Officer. Following this introduction, Dr. Steiner will highlight fourth-quarter and full-year 2008 corporate developments and our plans for 2009. Next, Mr. Hanover will briefly review our financial performance. Dr. Steiner will then make some closing remarks before opening the call to questions.

Before we begin, I remind you that information discussed on this call may include forward-looking statements and such statements are subject to the risks and uncertainties we discussed in detail in our reports filed with the Securities and Exchange Commission, including in our quarterly report on Form 10-Q filed November 5, 2008. We expressly disclaim any obligation to release publicly any updates to forward-looking statements made during the call

Now I'll turn the call over to Dr. Steiner.

Mitchell Steiner

Thank you, McDavid. 2009 will be an exciting and busy year for GTx. There are several major events that we anticipate from our four clinical development programs. As with the toremifene 80 milligrams dose to prevent fractures and treat other estrogen related side effects in men with prostate cancer and androgen deprivation therapy (ADT), we submitted the new drug application on December 30, 2008.

Copyright © 2008 CNET Networks, Inc. All Rights Reserved.